Clinical Trials Logo

Chronic Hepatitis C clinical trials

View clinical trials related to Chronic Hepatitis C.

Filter by:

NCT ID: NCT00418054 Completed - Chronic Hepatitis C Clinical Trials

Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C

Start date: December 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of nitazoxanide-peginterferon alfa-2b combination therapy compared to peginterferon monotherapy in patients that are treatment naive or pre-treated for 24 weeks with nitazoxanide monotherapy in the treatment of chronic hepatitis C.

NCT ID: NCT00411385 Completed - Chronic Hepatitis C Clinical Trials

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

Start date: February 2007
Phase: Phase 3
Study type: Interventional

This is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa-2b (alb-IFN)in combination with ribavirin compared with peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) in combination with ribavirin in subjects with chronic hepatitis C, genotype 2/3 who are IFNa treatment naive.

NCT ID: NCT00402428 Completed - Chronic Hepatitis C Clinical Trials

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients

Start date: December 2006
Phase: Phase 3
Study type: Interventional

This is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa 2b (alb-IFN)in combination with ribavirin compared with peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) in combination with ribavirin in subjects with chronic hepatitis C, genotype 1 who are IFNa treatment naive.

NCT ID: NCT00395421 Completed - Chronic Hepatitis C Clinical Trials

Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

Start date: October 2006
Phase: Phase 2
Study type: Interventional

This study is being conducted to see if the investigational medication, valopicitabine, is safe to use in combination with ribavirin, a drug approved by the FDA for treating hepatitis C infection.

NCT ID: NCT00372385 Completed - Chronic Hepatitis C Clinical Trials

Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

Start date: August 2006
Phase: Phase 2
Study type: Interventional

Compare the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) with and without Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels

NCT ID: NCT00352235 Completed - Chronic Hepatitis C Clinical Trials

Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection

Start date: August 2003
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II trial of KRN7000 in patients with chronic hepatitis C. Study objectives: To evaluate and compare the safety and tolerability of 3 ascending doses of a-GalCer. The primary efficacy parameter: HCV-RNA response at the end of treatment. Secondary efficacy parameter: Serum ALT response. Further objectives of the study are to evaluate the effect of a-GalCer on serum cytokines IFNg and TNFa and on iNKT cells. Number of dose levels: 3 Investigational product: KRN7000 Route of administration: intravenous Dosages and frequency: 0.1, 1, 10 mcg/kg, monthly injection, 3 times (day 0, day 28 and day 56)

NCT ID: NCT00351871 Completed - Chronic Hepatitis C Clinical Trials

Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy

Start date: April 2002
Phase: Phase 4
Study type: Interventional

The objective of this study is to better understand the influence of insulin resistance upon treatment response in hepatitis C virus treated with PEG Intron and Rebetol.

NCT ID: NCT00336479 Completed - Chronic Hepatitis C Clinical Trials

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

Start date: June 2006
Phase: Phase 2
Study type: Interventional

Study the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) and Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels

NCT ID: NCT00322179 Completed - Obesity Clinical Trials

Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C

Start date: November 2005
Phase:
Study type: Observational

The response rate to interferon-based anti-viral therapy for chronic hepatitis C is lower in patients who are obese. However, it is not clear whether this is related to suboptimal dosing of the medication or alterated response in obese patients. Alterated immune response had been reported in obese patients. The goal of current study is to determine the immune response to interferon in obese compared to non-obese chronic hepatitis C in an tissue culture system.

NCT ID: NCT00304551 Completed - Liver Cirrhosis Clinical Trials

A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)

Start date: June 2006
Phase: Phase 3
Study type: Interventional

This study evaluated the clinical response of the efficacy and safety of the combination therapy of peginterferon alfa-2a and ribavirin, compared with an antiviral treatment-free group in CHC patients with compensated LC. Additionally, this study evaluated the dosage reactivity and the pharmacokinetic characteristics of the combination therapy of peginterferon alfa-2a and ribavirin in CHC patients with compensated LC.